Celltrion has strengthened its footprint in Vietnam by introducing two oncology biosimilars, further expanding its portfolio in one of Southeast Asia’s rapidly growing pharmaceutical markets. The company announced that commercial sales of Truxima (rituximab), used in the treatment of hematologic malignancies, and Vegzelma (bevacizumab), indicated for multiple cancers including metastatic colorectal cancer and breast cancer, commenced in Vietnam. The launches follow marketing authorization granted in March, approximately three months before commercialization. Vietnam remains a strategic market for Celltrion within the ASEAN region. The addition of the two products increases the company’s local portfolio to four medicines, following the introduction of Remsima (infliximab) and Herzuma (trastuzumab) in the country last year.
The company said the expanded range will support broader adoption of its oncology biosimilars and other biosimilar products in Vietnam. Celltrion’s local subsidiary plans to leverage the hospital network and tender experience it established through Herzuma’s commercialization. According to the company, its Vietnam operation secured 25 of 48 trastuzumab tenders conducted by major hospitals nationwide after Herzuma entered the market. Celltrion stated that this experience is expected to support the rollout of newly launched products and strengthen its position in public procurement channels.
Celltrion also highlighted the performance of its biosimilars across Asia. Data from IQVIA cited by the company showed that Remsima commands a 96 percent market share in Singapore and leads the infliximab market in Thailand and Malaysia with shares of 77 percent and 59 percent, respectively. Remsima SC, the subcutaneous formulation of infliximab, has reached a 29 percent market share in Hong Kong, while the combined Remsima franchise has achieved an 82 percent share. Among the company’s oncology biosimilars, Herzuma leads the trastuzumab market in Thailand with an 82 percent share and holds market shares of 64 percent in Hong Kong and 53 percent in Malaysia. Truxima has also recorded market shares of 81 percent in Singapore and 74 percent in Thailand.
Beyond Asia, Celltrion continues to expand its presence in Latin America. The company reported that Remsima and Truxima each hold nearly 100 percent market share in their respective markets in Costa Rica, while Truxima has reached about 80 percent in Ecuador. Remsima maintains roughly 80 percent market share in both the Dominican Republic and Paraguay. Looking ahead, Celltrion plans additional product launches and participation in public tenders across emerging markets. In Vietnam, preparations are underway for the introduction of follow-up products including Remsima SC, while Indonesia is expected to see further launches through the company’s local subsidiary. The company also intends to broaden its Latin American presence with new products, including Omlyclo, alongside increased participation in government procurement tenders.
